Clinical data of fluocortin butylester (FCB) - a new inhalable corticoid.
A report was given on a new inhalable corticoid - Fluocortin butylester (FCB) - administered to patients with bronchial asthma. Forty eight cases with extrinsic asthma induced by allergen challenge participated in this study. A good protective effect was seen in 10 patients inhaling 8 mg daily. This dosis produced a remarkable effect of Raw and FRC. No side effects were observed in a study carried over 3 years. Furthermore, there was detected a normal adrenal function during the duration of FCB therapy.
D000336:Aerosols; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005448:Fluocortolone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine
D000336:Aerosols; D001993:Bronchodilator Agents; D005448:Fluocortolone; C011824:fluocortin butyl ester; D006854:Hydrocortisone